Protalix BioTherapeutics (PLX) Price Target Drops 12% to $11.22 Share

Protalix BioTherapeutics' (PLX) average one-year price target has been revised to $11.22/share, a decrease of 12% from the prior estimate of $12.75/share. The target is an average of analysts' targets, ranging from $10.10 to $12.60/share. There are 132 funds or institutions reporting positions in PLX, with an average portfolio weight of 0.01%. The put/call ratio of PLX is 0.08, indicating a bullish outlook.